POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?
Click here to answer this week's poll for Hyperhidrosis Awareness Month.
American Indian/Alaska Native Communities Face Barriers to Dermatologic Care, Disparities, and More
November is Native American Heritage Month. Access to dermatological health care has been a persistent challenge for individuals in the AIAN community.
Cancer Vaccine Plus Keytruda Improves Survival Without Relapse in Resected Melanoma
Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma.
Majority of Dermatologists in US Prescribe Baricitinib to Patients With Alopecia Areata, Report Shows
Baricitinib is more commonly prescribed by dermatologists for patients with alopecia in the US and is projected to maintain a substantial market lead over ritlecitinib.
Frontline Forum Part 1: Topical Therapy for Corticosteroid-Responsive Dermatoses
Experts discuss enhancing patient outcomes, the "mounting mutiny" against topicals, and more.
FDA Grants Breakthrough Therapy Designation to QTORIN Rapamycin for Microcystic Lymphatic Malformations
There are currently no FDA-approved therapies for the rare, genetic disease.
Revolutionizing Vitiligo Care: Dermatology Experts Offer Insights on Economic Factors
Experts Heather Woolery-Lloyd, MD; Chesahna Kindred, MD, MBA, FAAD; Gary M. Owens, MD; and Renata Block, MMS, PA-C, discuss the evolving landscape of vitiligo, particularly from an economic lens.
Almirall, Absci Partner to Develop AI-Designed Therapies for Dermatologic Conditions
The partnership will combine dermatological expertise and Absci's Integrated Drug Creation platform.
The Journal Digest: November 15
This week’s collection of the latest dermatologic studies covers atypical molluscum contagiosum lesions with a CD30-positive T-cell lymphoid infiltrate, comorbidities in pediatric psoriasis, tralokinumab for adolescents with severe AD, and intralesional bleomycin combined with lidocaine for recalcitrant keloid scars.
Dermatology Community Celebrates Nurse Practitioners This NP Week
Dermatology Times, the SDPA, and more are celebrating the invaluable contributions of nurse practitioners in dermatology this NP Week (November 12-18).
No Significant Difference in BMI, Weight Regarding Switching Rates for Patients with Psoriasis
Label warnings may affect the initiation of new treatment and real-world switching patterns for psoriasis patients starting treatment with risankizumab.
Aging, Acne, and the Armamentarium: Hot Topics From the Science of Skincare Summit
Experts discuss insights and hot topics stemming from this year's Science of Skincare Summit, including upcoming innovations and considerations in dermatology.
Nonablative Lasers Offer a Gentle Approach to Healthy Skin
In honor of National Healthy Skin Month, it is the perfect time to encourage patients to integrate gentle laser treatments into their yearly routine to maintain healthy, radiant skin.
UCB's Bimekizumab is Now Available
Bimekizumab is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.
Tildrakizumab Significantly Improved Work Productivity and More in Patients With Plaque Psoriasis
In addition to improvements in work productivity, tildrakizumab also demonstrated significant efficacy and safety.
The Amazingly Wide, Ever-Expanding Reach of Dermatology
Dermatology encompasses cosmetics, unregulated products, OTC drugs, OTC devices, prescription devices, and prescription drugs, whether oral, injectable, or topical.
Reflecting on a Year of Meaningful Innovations
2023 has been complete with numerous innovations in the dermatology space, including in atopic dermatitis, psoriasis, alopecia areata, and more.
Pointers With Portela: Understanding Health Insurance
In this week’s Pointers With Portela, the 208SkinDoc reviews medical health insurance on his podcast.
Derm In The News: November 5-11
Keep up with the latest headlines in dermatology from the past week, including the rise of teledermatology platforms leading patients to opt out of in-person consultations, WHO and ILO estimates of non-melanoma skin cancer deaths attributable to outdoor work in the sun, and more.
The Weekly Roundup: November 6-10
ICYMI, this week we had articles about a proposed ban of formaldehyde in hair relaxers, TAK-279 for psoriatic arthritis, and updated atopic dermatitis guidelines from AAD.
Nemolizumab Significantly Reduces Itch and Improves DLQI in Patients With Prurigo Nodularis
Shawn Kwatra, MD, shares his thoughts on the positive phase 3 data of OLYMPIA 2.
Highlights From 2023 NP & PA Conferences: Part 2
Catch up on the best highlights from Maui Derm NP + PA Fall, Inflammatory Disease Summit, and SDPA Fall.
National Rosacea Society Awards 2023 Grants for Research
Grants allow investigators to uncover the potential causes and key aspects of rosacea to pave the way for improved treatment, prevention, and possibly a cure.
Experts Excited by Advancements in Vitiligo Treatment
Susan C. Taylor, MD, FAAD, and George Han, MD, PhD, share insights on vitiligo awareness, demographics, treatment approaches, and the impact of the condition on patients’ quality of life.
Patients With Mild Psoriasis Experience Less Favorable Status at Diagnosis and First Line of Treatment
Investigators noted that patients with mild psoriasis experience a less favorable status when compared to patients with moderate psoriasis.
Remibrutinib Improves Chronic Spontaneous Urticaria Symptoms at Week 2
Data from Novartis will be presented at the 2023 American College of Allergy, Asthma, and Immunology Scientific Meeting.
POLL: What Treatment Option Do You Most Commonly Use for Patients With Hyperhidrosis?
Click here to answer this week's poll for hyperhidrosis awareness month.
Evaluating Stress Levels in AD Treatment Plans
The case of a 45-year-old woman with AD challenges clinicians on how to consider stress as an exacerbating factor in a treatment-resistant case.
Highlights From 2023 NP & PA Conferences: Part 1
Catch up on the best highlights from Fall Clinical for PAs & NPs, SDPA Summer, and Maui Derm NP + PA Summer.
Updated AAD Guidelines for the Management of AD with Phototherapy and Systemic Therapies
The guidelines update AAD’s 2014 recommendations for the management of AD with phototherapy and systemic therapies.
2 Clarke Drive Cranbury, NJ 08512